Recruiting for COVID clinical trial

NORSTM as an upper airway “disinfectant”

SaNOtize has demonstrated the effectiveness of its NORS formulation in eradicating different types of viruses, including influenza and H1N1, and is working diligently to determine NORS’ efficacy to prevent and treat COVID-19 infections.

At present, SaNOtize:

  • Has received Health Canada approval for a multi-centre, randomized, controlled, Phase II efficacy study evaluating NORS TM for the prevention and treatment of COVID-19 in healthcare workers and individuals at risk of infection;
  • Has confirmed NORSTM is >99.9% effective against different types of coronaviruses (including SARS-CoV-2, the virus that causes COVID-19) in tests conducted by the independent Institute for Antiviral Research at Utah State University;
  • Has applied to the FDA for Emergency Utilization Authorization for use on people with an emphasis on availability for healthcare workers; and
  • Is working with a leading hospital in Israel to commence a clinical trial to determine the efficacy of NORS in prevention of COVID-19

For more information about SaNOtize, NORSTM and our potential to bring to market antiviral hand sanitizer, nasal spray and deep sinus wash products shown to be safe and effective in combatting COVID-19

Check our Discussion Paper

Download our Discussion Paper

Send download link to:

By entering your contact info and downloading the materials, you understand that: a) SaNOtize will use your email to provide you with company updates; b) You can unsubscribe at any time; and c) SaNOtize will not sell or share your information to any third party

logged in